Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,721 to 1,740 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: All-cause Mortality | 68 of 2,526 87 of 2,526 | -0.8 points -1.7 to 0.2 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Thrombotic Stroke | 13 of 2,526 7 of 2,526 | 0.2 points -0.1 to 0.6 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Stent Thrombosis | 34 of 2,526 32 of 2,526 | 0.1 points -0.6 to 0.7 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Non-cardiovascular Death (Including Fatal Bleeding) and Major Non-fatal Bleeding | 104 of 2,526 127 of 2,526 | -0.9 points -2.1 to 0.2 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Coronary Revascularisation | 286 of 2,526 259 of 2,526 | 1.1 points -0.6 to 2.8 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Myocardial Infarction (Fatal and Non-fatal) | 221 of 2,526 203 of 2,526 | 0.7 points -0.8 to 2.2 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Cardiovascular Death and Non-fatal Myocardial Infarction | 236 of 2,526 226 of 2,526 | 0.4 points -1.2 to 2.0 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: deaths from any cause | 68 of 2,526 87 of 2,526 | -0.8 points -1.7 to 0.2 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Intracranial Haemorrhage | 0 of 2,526 10 of 2,526 | -0.4 points -0.7 to -0.2 | 5,052 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| Vericiguat vs Placebo: deaths from any cause | 553 of 2,526 561 of 2,524 | -0.3 points -2.6 to 2.0 | 5,050 | NCT02861534 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) |
| Clinical Decision Support for BUP vs Usual Care: Count of Those With Referral to Follow-up for Ongoing MOUD Treatment (Patient Level) | 367 of 2,787 226 of 2,260 | 3.2 points 1.4 to 4.9 | 5,047 | NCT03658642 Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD |
| Clinical Decision Support for BUP vs Usual Care: Count of Initiating BUP in the ED With Referral for Ongoing MOUD With User-centered CDS Compared With Usual Care | 347 of 2,787 271 of 2,260 | 0.5 points -1.4 to 2.3 | 5,047 | NCT03658642 Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD |
| Convalescent Plasma Group vs Non-plasma Group: deaths from any cause | 40 of 402 343 of 4,642 | 2.6 points -0.1 to 6.0 | 5,044 | NCT04545047 Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 |
| Individualized Opioid Prescription Protocol (IOPP) vs Fixed Opioid Prescription: Number of Participants Who Indicated an Improved Global Impression of Change | 2,436 of 2,528 2,436 of 2,509 | -0.7 points -1.7 to 0.3 | 5,037 | NCT04296396 Opioid Prescription After Cesarean Trial |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 287 of 2,500 309 of 2,535 | -0.7 points -2.5 to 1.1 | 5,035 | NCT02867813 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension |
| Vericiguat vs Placebo: Number of Participants Who Experienced One or More Adverse Events | 2,027 of 2,519 2,036 of 2,515 | -0.5 points -2.7 to 1.7 | 5,034 | NCT02861534 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) |
| Vericiguat vs Placebo: Number of Participants Who Discontinued Treatment Due to an Adverse Event | 167 of 2,519 158 of 2,515 | 0.3 points -1.0 to 1.7 | 5,034 | NCT02861534 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) |
| Vericiguat vs Placebo: serious adverse events | 852 of 2,519 897 of 2,515 | -1.8 points -4.5 to 0.8 | 5,034 | NCT02861534 A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) |
| Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 2,084 of 2,499 2,144 of 2,532 | -1.3 points -3.3 to 0.7 | 5,031 | NCT02867813 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 1,045 of 2,499 1,077 of 2,532 | -0.7 points -3.4 to 2.0 | 5,031 | NCT02867813 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=87
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03252249-24eac003",
"title": "3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: All-cause Mortality",
"summary": "68 of 2526 against 87 of 2526; risk difference -0.8 points, 95% interval -1.7 to 0.2; NCT03252249, Duration of Dual Anti-Platelet Therapy (DUAL-ACS)",
"record": "/library/comparisons/NCT03252249-24eac003",
"nct_id": "NCT03252249",
"kind": "outcome",
"participants": 5052,
"risk_difference": {
"value": -0.00752177355502771,
"lower": -0.01718004947090889,
"upper": 0.0020348100889991012
},
"group_1": "68 of 2,526",
"group_2": "87 of 2,526",
"difference": "-0.8 points",
"interval": "-1.7 to 0.2",
"trial_title": "Duration of Dual Anti-Platelet Therapy (DUAL-ACS)"
},
{
"id": "NCT03252249-4d4609c6",
"title": "3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Thrombotic Stroke",
"summary": "13 of 2526 against 7 of 2526; risk difference 0.2 points, 95% interval -0.1 to 0.6; NCT03252249, Duration of Dual Anti-Platelet Therapy (DUAL-ACS)",
"record": "/library/comparisons/NCT03252249-4d4609c6",
"nct_id": "NCT03252249",
"kind": "outcome",
"participants": 5052,
"risk_difference": {
"value": 0.0023752969121140144,
"lower": -0.001257473998289143,
"upper": 0.0062846706102963
},
"group_1": "13 of 2,526",
"group_2": "7 of 2,526",
"difference": "0.2 points",
"interval": "-0.1 to 0.6",
"trial_title": "Duration of Dual Anti-Platelet Therapy (DUAL-ACS)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=88",
"request_id": "HVVvjpjUf96XXBGz"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant